Literature DB >> 22458993

Psychiatric disorders in Huntington's disease: a 2-year follow-up study.

W Reedeker1, R C van der Mast, E J Giltay, T A D Kooistra, R A C Roos, E van Duijn.   

Abstract

OBJECTIVE: This study investigates the presence and course of formal psychiatric disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) in 142 Huntington's disease (HD) mutation carriers in a two-year follow-up design.
METHOD: Of the 142 mutation carriers, 106 (75%) participated in the second measurement of an ongoing cohort study on psychopathology in HD. Presence of psychiatric disorders was assessed using the Composite International Diagnostic Interview.
RESULTS: Of the 91 patients without a formal psychiatric disorder at baseline, 14 (15%) had a psychiatric disorder after 2 years, mostly a major depressive disorder (MDD) (64%). The baseline characteristics of lower education, having no children, a lower level of global daily functioning, a lifetime psychiatric diagnosis, and the use of psychotropic medication were predictive of incident psychiatric disorders after 2 years. Of the 15 patients with a psychiatric diagnosis at baseline, eight (53%) no longer had a psychiatric disorder at follow-up. All seven patients (47%) with a persistent psychiatric disorder were female and their most prevalent diagnosis was generalized anxiety disorder.
CONCLUSION: This cohort study confirms that psychiatric disorders, in particular MDD, frequently occur in patients with HD. Professionals working with HD patients should therefore be aware of the high risk of psychopathology in HD because early diagnosis and treatment of psychiatric disorders may improve the quality of life of patients and their caregivers.
Copyright © 2012 The Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22458993     DOI: 10.1016/j.psym.2011.12.010

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  12 in total

1.  Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Authors:  Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2019

2.  Psychosis with Huntington's disease: role of antipsychotic medications.

Authors:  Jonathan Ding; Amin Muhammad Gadit
Journal:  BMJ Case Rep       Date:  2014-08-19

3.  Calcium dysregulation and compensation in cortical pyramidal neurons of the R6/2 mouse model of Huntington's disease.

Authors:  Katerina D Oikonomou; Elissa J Donzis; Minh T N Bui; Carlos Cepeda; Michael S Levine
Journal:  J Neurophysiol       Date:  2021-09-01       Impact factor: 2.974

Review 4.  Huntington's Chorea-a Rare Neurodegenerative Autosomal Dominant Disease: Insight into Molecular Genetics, Prognosis and Diagnosis.

Authors:  Pratik Talukder; Annapurna Jana; Shrirupa Dhar; Saikat Ghosh
Journal:  Appl Biochem Biotechnol       Date:  2021-07-07       Impact factor: 2.926

Review 5.  Role of cerebral cortex in the neuropathology of Huntington's disease.

Authors:  Ana M Estrada-Sánchez; George V Rebec
Journal:  Front Neural Circuits       Date:  2013-02-18       Impact factor: 3.492

Review 6.  Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms.

Authors:  Patrick Pla; Sophie Orvoen; Frédéric Saudou; Denis J David; Sandrine Humbert
Journal:  Front Behav Neurosci       Date:  2014-04-23       Impact factor: 3.558

Review 7.  Neuropsychiatric Burden in Huntington's Disease.

Authors:  Ricardo Augusto Paoli; Andrea Botturi; Andrea Ciammola; Vincenzo Silani; Cecilia Prunas; Claudio Lucchiari; Elisa Zugno; Elisabetta Caletti
Journal:  Brain Sci       Date:  2017-06-16

8.  Understanding domains that influence perceived stigma in individuals with Huntington disease.

Authors:  Nicholas R Boileau; Jane S Paulsen; Rebecca E Ready; Elizabeth A Hahn; Jin-Shei Lai; Noelle E Carlozzi
Journal:  Rehabil Psychol       Date:  2020-01-20

9.  Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD).

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Matthew W Roché; Rebecca E Ready; Joel S Perlmutter; Kelvin L Chou; Stacey K Barton; Michael K McCormack; Julie C Stout; David Cella; Jennifer A Miner; Jane S Paulsen
Journal:  Qual Life Res       Date:  2020-08-19       Impact factor: 4.147

10.  Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse.

Authors:  Sofia Hult Lundh; Rana Soylu; Asa Petersén
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.